This provider's $27.4M in total Medicare payments ranks in the 96th percentile of Clinical Laboratory providers nationally.
Medicare payments to this provider grew 1232% from 2017 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 601% in 2018
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2017 | $231.90 | $190.14 | 1.22x | $41.76 | $398.0K | 2.1K | 3 |
| 2018 | $234.75 | $179.40 | 1.31x | $55.35 | $2.8M | 15.5K | 4 |
| 2019 | $115.20 | $82.26 | 1.40x | $32.94 | $3.8M | 45.9K | 12 |
| 2020 | $72.78 | $49.12 | 1.48x | $23.66 | $4.5M | 90.7K | 15 |
| 2021 | $61.92 | $42.55 | 1.46x | $19.37 | $4.4M | 102.7K | 12 |
| 2022 | $57.95 | $41.95 | 1.38x | $16.00 | $6.3M | 150.8K | 20 |
| 2023 | $60.35 | $43.33 | 1.39x | $17.02 | $5.3M | 122.3K | 18 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | 186.4K | $6.6M | $35.47 | 1.51x |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 67.2K | $5.1M | $76.19 | 1.34x |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 18.9K | $4.6M | $243.12 | 1.23x |
| 87633 | Detection test for multiple types of respiratory virus | 4.4K | $2.1M | $484.86 | 1.34x |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 66.2K | $1.5M | $23.16 | 1.51x |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within | 60.9K | $1.5M | $24.65 | 1.22x |
| 87481 | Detection test for candida species (yeast), amplified probe technique | 33.1K | $1.2M | $35.36 | 1.72x |
| 87631 | Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets | 7.6K | $1.1M | $141.87 | 1.65x |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 18.0K | $906.2K | $50.28 | 1.48x |
| 87581 | Detection test by nucleic acid for mycoplasma pneumoniae (bacteria), amplified probe technique | 13.8K | $509.8K | $36.88 | 1.57x |
| 87486 | Detection test by nucleic acid for chlamydia pneumoniae, amplified probe technique | 13.8K | $509.8K | $36.88 | 1.58x |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 7.0K | $247.7K | $35.42 | 1.28x |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 6.8K | $239.4K | $35.10 | 1.30x |
| 87541 | Detection test by nucleic acid for legionella pneumophila (water borne bacteria), amplified probe technique | 6.7K | $235.5K | $35.10 | 1.29x |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 6.5K | $228.4K | $35.07 | 1.30x |
| 87507 | Detection test by nucleic acid for digestive tract pathogen, multiple types or subtypes, 12-25 targets | 390 | $188.4K | $483.07 | 1.32x |
| 87150 | Identification of organisms by genetic analysis, amplified probe technique | 5.1K | $178.4K | $34.94 | 1.29x |
| 0100U | Test for detection of respiratory disease-causing organism using amplified probe, 20 target organisms (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, inc | 339 | $99.2K | $292.63 | 1.37x |
| 87551 | Detection test by nucleic acid for mycobacteria species (bacteria), amplified probe technique | 1.8K | $87.0K | $47.28 | 1.27x |
| 87561 | Detection test by nucleic acid for mycobacteria avium-intracellulare (bacteria), amplified probe technique | 1.8K | $63.6K | $34.39 | 1.31x |
This provider submits charges 1.4 times higher than what Medicare actually pays.
A markup ratio of 1.4x means for every $100 Medicare pays, this provider initially charges $140. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Clinical Laboratory providers in CA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Genomic Health, Inc. | Redwood City, CA | $887.6M | ✓ Clear |
| Unilab Corporation | West Hills, CA | $868.8M | ⚠️ Flagged |
| Caredx Inc. | Brisbane, CA | $751.0M | ✓ Clear |
| Laboratory Corporation Of America | San Diego, CA | $592.4M | ⚠️ Flagged |
| Millennium Health, Llc | San Diego, CA | $587.9M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data